Skip to main content

ProQR Therapeutics N.V.

corporate_fare Company Profile

ProQR Therapeutics N.V.

PRQR·NASDAQ·Life Sciences·CIK 0001612940

ProQR Therapeutics N.V. is a clinical-stage biotechnology company focused on discovering and developing new therapeutic medicines. The company develops an RNA editing platform using its Axiomer RNA editing technology, aimed at treating genetic disorders where current treatments are insufficient. Its primary product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. ProQR also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. The company has a research and collaboration agreement with Eli Lilly and Company to discover, develop, and commercialize potential new medicines for genetic disorders affecting the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics N.V. (NASDAQ:PRQR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for PRQR at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • ProQR Reports Q1 2026 Results, Advances RNA Editing Pipeline, and Refines Lead Program Strategy
  • Shareholders to Vote on Major Capital Increase and Share Issuance Authority
  • ProQR Nominates Pharma Veteran Dr. Lykke Hinsch Gylvin to Board of Directors
  • ProQR Details Expanded RNA Editing Pipeline, New Programs, and Clinical Milestones
  • ProQR Unveils Expanded Pipeline, Targets Multiple Clinical Data Readouts Through Mid-2027

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
€15.91M EUR
Net Income
-€42.18M EUR
Diluted EPS
-€0.40 EUR
Op. Cash Flow
-€52.79M EUR
Free Cash Flow
-€53.81M EUR
Operating Income
-€43.45M EUR
Cash & Equivalents
€92.41M EUR
Debt / Equity
0.00×
Net Margin
-265.2%
Source: 20-F · filed 2026-03-12 · accession 0001104659-26-026713

Insider Transactions

PRQR files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$1.04 -0.95% today
52-week range · as of 2026-11-12 $1.04 – $2.48
Market cap
$146.77M
Volume
920.6K (1.1× avg)
3-mo avg 861.2K
Live data · 2026-11-22 12:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PRQR - Filings & News (Page 2)

PRQR
May 12, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.59
Real-time Price: $1.04 info
Change: -$0.550 (-35%) info
Market Cap: $146.766M info
PRQR
May 04, 2026, 8:05 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.51
Real-time Price: $1.04 info
Change: -$0.470 (-31%) info
Market Cap: $146.766M info
PRQR
Apr 30, 2026, 8:10 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.59
Real-time Price: $1.04 info
Change: -$0.550 (-35%) info
Market Cap: $146.766M info
PRQR
Apr 08, 2026, 4:06 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.93
Real-time Price: $1.04 info
Change: -$0.890 (-46%) info
Market Cap: $146.766M info
PRQR
Apr 08, 2026, 4:00 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.95
Real-time Price: $1.04 info
Change: -$0.910 (-47%) info
Market Cap: $146.766M info
PRQR
Apr 08, 2026, 8:07 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.79
Real-time Price: $1.04 info
Change: -$0.750 (-42%) info
Market Cap: $146.766M info
PRQR
Mar 25, 2026, 8:01 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $1.04 info
Change: -$0.480 (-32%) info
Market Cap: $146.766M info
PRQR
Mar 12, 2026, 7:22 AM EDT
Filing Type: 20-F
Importance Score:
7
Price at Filing: $1.78
Real-time Price: $1.04 info
Change: -$0.740 (-42%) info
Market Cap: $146.766M info
PRQR
Mar 12, 2026, 7:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.78
Real-time Price: $1.04 info
Change: -$0.740 (-42%) info
Market Cap: $146.766M info
PRQR
Mar 12, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.78
Real-time Price: $1.04 info
Change: -$0.740 (-42%) info
Market Cap: $146.766M info
PRQR
Feb 06, 2026, 4:01 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $1.04 info
Change: -$0.460 (-31%) info
Market Cap: $146.766M info
PRQR
Jan 08, 2026, 8:08 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.29
Real-time Price: $1.04 info
Change: -$1.25 (-55%) info
Market Cap: $146.766M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets